ArticlePloS one2025
In silico design of a multi-epitope vaccine against Cryptosporidium parvum using structural and immunoinformatics approaches.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCryptosporidium parvum is a waterborne protozoan parasite responsible for diarrheal illness in humans and animals. The lack of effective vaccines and the emergence of antimicrobial resistance underscore the urgent need for novel prophylactic strategies.
methodsA structure-based immunoinformatics approach was used to design a multi-epitope subunit vaccine (MESV) targeting immunogenic regions of C. parvum. Three proteins, Cp15, Cp23, and CpP2, were selected based on antigenicity, non-allergenicity, non-homology with host proteins, and absence of transmembrane domains. B-cell, CD4+, CD8+, and IFN-γ-inducing epitopes were identified and screened for high antigenicity, non-allergenicity, and non-toxicity. To enhance immune recognition, the lipoprotein LprA, a TLR2 agonist, was fused at the N-terminus using an EAAAK linker, and a PADRE sequence was added to improve helper T-cell responses. Linkers were applied to ensure proper epitope separation and processing. Population coverage was analyzed to evaluate the distribution of HLA-restricted epitopes across global populations. Structural modeling and flexibility analysis (CABS-flex) were performed to assess construct stability. Interactions with TLR2 and TLR4 were examined via molecular docking and 100-ns molecular dynamics (MD) simulations, with MM-GBSA used to estimate binding free energies. Immune simulations predicted host immune responses, while codon optimization, in silico cloning, and mRNA secondary structure prediction assessed expression and transcript stability.
resultsThe MESV showed strong binding to TLR2 (-1328.4 kcal/mol) and TLR4 (-1133.3 kcal/mol), with MD simulations confirming stable complexes. Immune simulations indicated robust antibody production, T-cell activation, cytokine release, and dendritic cell recruitment. The vaccine demonstrated global HLA population coverage of 95.92%, with favorable expression and mRNA folding profiles.
conclusionThe MESV construct demonstrated strong immunogenicity, structural stability, and broad population coverage, underscoring its potential as a promising vaccine candidate against C. parvum. Furthermore, experimental validation is warranted to confirm its safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.